Helix Biopharma Corp. Announces Strategic Management Changes

(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that Dr. Sven Rohmann, CEO and Chairman of the Company, will be stepping down from his position as Chief Executive Officer of Helix BioPharma Corp., effective March 31, 2017, in order to focus his activities on chairing the board and to act as strategic advisor to the Company. Stepping into the
role of Chief Executive Officer will be Dr. Heman Chao, effective March 31, 2017. Dr. Chao has been Chief Scientific Officer of the Company since December 2008, and will remain Chief Scientific Officer, as well as assuming the position of Chief Executive Officer.